Mauldin Economics’ biotech and longevity letter, Transformative Age, is designed to be the go-to source for the latest breakthroughs in this rapidly evolving field. It brings together leading experts who are at the forefront of this fast-moving revolution. The biotech advances now unfolding have the potential to transform everything—from our health to our portfolios. Everyone should be aware of these accelerating breakthroughs, especially for the investment opportunities they present.
We already know how to slow aging, and many doctors agree we’re on the cusp of stopping or even reversing it. With each passing year, we open the door to the possibility of dramatically extending our lives to a healthy 100 years or more—and that’s being very conservative. This is not just about longevity; it’s about living healthier, fuller lives while unlocking transformative opportunities.
“I think we finally have the right team to turn my passion for longevity and biotech into something truly groundbreaking.”
John Mauldin
Mauldin Economics has been featured in
Right now, the developments happening in the longevity and biotech space are mostly hidden from the masses. Unless you’re on the inside, it’s hard to discern the quantum leaps taking place.
For example, you’ve likely heard of CRISPR—the revolutionary genome editing technology that allows scientists to modify DNA in living organisms.
But what you may not know is that CRISPR is already changing people’s lives.
Just ask Victoria Gray, the first patient with sickle cell disease to receive an experimental CRISPR treatment. Today, all of her symptoms are gone.
Then there’s Aissam Dam, an 11-year-old deaf boy who received a gene editing injection… and can now hear for the first time.
At fourteen, Antonio Carvajal was legally blind. Today, he can see thanks to CRISPR eye drops.
Right now, researchers are capitalizing on microgravity in space to accelerate drug discovery and development.
Merck recently ran experiments on the International Space Station to finetune their bestselling anti-cancer drug, Keytruda.
The results could revolutionize the cancer treatment experience. Instead of having to sit through long and painful chemotherapy treatments… a patient could get a shot in a doctor’s office.
At the same time, more and more scientists agree that aging itself can be stopped or potentially even reversed. Already, researchers have reset cellular aging in various species, using so-called Yamanaka genes.
For so long, the healthcare industry has seemed stuck in this purgatory of red tape and soon-to-be-released breakthrough therapies. We’ve basically been told to patiently… wait, wait, wait.
Now the evidence suggests the wait is finally over. In fact, the CEO of AI leader Anthropic predicts we could squeeze a century’s worth of biotech progress into the next 5–10 years.
That’s why Patick Cox, a foremost expert on longevity who’s on a first-name basis with Nobel Prize-winning scientists, says there’s now evidence that…
You may recognize Pat Cox as our longtime friend and former editor at Mauldin Economics.
He left to take a once-in-a-lifetime opportunity as Chief Scientific Officer at an anti-aging startup with Dr. Mike Roizen of Cleveland Clinic.
Now, Patrick is coming back to help lead the longevity arm of Transformative Age.
Because he believes the major breakthroughs that will ultimately cure aging have already been made.
Now, it’s just a matter of regulatory approval and acceptance by the medical establishment.
Things are about to get interesting as…
Semaglutide, the drug best known as Ozempic, was originally prescribed to treat diabetes.
Then scientists discovered it could also melt copious amounts of fat. It quickly became a blockbuster diet drug.
More than a fad, it’s ushered in what is being called an “important moment” in the field of weight management. In fact, Novo Nordisk, its Danish inventor, is now the most valuable company in Europe after its share price surged from $35 to $130.
Thanks to its success, a new wave of experimental drugs is currently being developed that go beyond diabetes and weight loss. These next generation GLP-1 drugs could improve liver and heart function, and even preserve lean body mass.
In fact, there are so many drug candidates in the pipeline right now…
it’s being called “an unprecedented acceleration.”
It’s just one of the many data points that’s led Patrick Cox to conclude we are on the verge of reversing age and dramatically extending healthy lifespans.
BUT… this information is not easily accessible. You won’t find it doing a Google search or talking to your health care provider.
You have to know where to look and who to talk to—if you want to get real answers. And that’s a big problem. Because sadly…
Remember when the ALS Ice Bucket Challenge was a global phenomenon?
Well, did you know that 1% of ALS is now 100% curable? Yes, right now.
But here’s the thing: only two hospitals in the world provide this groundbreaking treatment.
Imagine if you or a loved one had that curable form of ALS and didn’t know about these two hospitals? You’d be needlessly suffering, wasting away when you didn’t need to.
That’s why one of the big goals of Transformative Age is to let our members know about these groundbreaking developments as they become available.
Potentially years before the general public ever hears about them.
In short, not only could the insights in Transformative Age improve (or save) your life… it could let you dramatically help your friends and loved ones.
Just last year, a founding partner of Mauldin Economics had a friend who was diagnosed with final stage prostate cancer.
This Mauldin Economics partner happened to have a connection at an Ivy League medical center. He advised the friend to get a 2nd opinion at a specialized hospital at the forefront of advanced prostate cancer research.
The friend received cutting-edge, specialized treatment that most cancer doctors don’t know about.
One year later, he’s back to running 5Ks. He was able to attend his class reunion in Tuscany, then stop by Sicily with his wife.
All because of a serendipitous connection… that led to what can only be described as a personal miracle.
In short, this friend is living a healthy life today because of his access to this “hidden” information.
For example, aging is no longer a mystery. In fact, many scientists now agree we’re on the cusp of a dramatic jump in human life expectancy.
One doctor believes humans will one day live to be 1,000, much like Methuselah and other patriarchs mentioned in the Old Testament.
While David Sinclair, a geneticist at Harvard University, suggests that living into our hundreds healthily could become a reality within the next few decades.
It sounds like science fiction. But it’s not.
Because there’s a firm scientific basis for these longevity beliefs:
Telomere Extension
Telomeres protect the ends of your chromosomes, like the plastic caps on shoelaces. As we age they shorten, which leads to programmed cell death.
Researchers are exploring ways to lengthen telomeres, which could stop cellular aging and cure aspects of age-related decline.
Dr. Michael West, co-founder of AgeX Therapeutics, is researching ways to activate embryonic gene pathways to reverse biological age.
While biotech company Telocyte is focused on using telomere extension to treat Alzheimer’s disease.
Senolytic Drugs
By removing senescent cells, which contribute to aging, senolytic drugs could extend healthspan significantly.
A well-known study by the Mayo Clinic and Scripps Research demonstrated that clearing senescent cells could extend lifespan by up to 36%.
The most prominent company in this field is Unity Biotechnology. One of their drugs has advanced to Phase II trials.
Yamanaka Factors
The partial reprogramming of cells using Yamanaka factors has shown promising results in reversing aging.
Scientists working with Yamanaka factors have taken mature cells and reverted them to an embryonic-like state. This effectively “resets” the cells, erasing the biological markers of age.
Studies at the Salk Institute, Harvard University, and Stanford University are very promising.
Causing one of the scientists to say…
—Dr. Hal Barron
Backed by investors like Jeff Bezos and Yuri Milner, Atlos Labs is a major player in biological reprogramming using Yamanaka factors.
While these technologies are not yet in widespread use… they are some of the most exciting avenues for dramatically extending human healthspan.
In short, with every year we live… we open the door to the possibility of extending our life to a healthy 100, or more.
That’s why this information is more important than ever.
Transformative Age is your trusted source for the latest longevity and biotech breakthroughs.
Built on over a year of preparation and hundreds of hours of collaboration, this advisory brings together a world-class league of experts handpicked to deliver cutting-edge insights and actionable strategies.
John is deeply passionate about biotech and longevity, and he’s assembled a team capable of turning that vision into something truly groundbreaking.
Let’s start with the investing focus of Transformative Age. For that, we chose Chris Wood:
Chris is a 20-year market veteran who is one of the best financial analysts we know. And one of the most hardworking. It’s not unusual to find him sleeping at the office when he’s racing to get an urgent investment recommendation in his readers’ hands ASAP.
Chris’s hard work often pays off for his subscribers. He first published bullish research on Google and Amazon in 2012, and Nvidia in 2013 when it was trading for under $0.29, split-adjusted. At Mauldin Economics, he’s our most trusted mentor for younger analysts.
Chris has been deeply involved in biotech investing since 2012. He was one of the first investment analysts to assert that AI would disrupt and accelerate drug discovery—a prediction he made 2 years before ChatGPT existed. That’s now coming true before our eyes.
Above all else, Chris knows the right people in biotech. He has relationships with 50+ biotech CEOs, as well as several biotech fund managers and capital allocators.
What’s more, Chris’s own life has been transformed thanks to the latest biotech innovations.
Over the past 1-1/2 years, he’s lost 85 pounds and has dramatically improved his life and health.
Before/After
Chris was an athlete his entire life. He even played on the Texas Longhorns championship team behind running back Ricky Williams. But then a string of injuries, bad health episodes, and a brutal work schedule caused him to put on a lot of weight. He was diagnosed with type 2 diabetes at the age of 32 and at his most weighed 269 lbs.
How did his incredible transformation take place?
It all started the day his doctor prescribed the GLP-1 drug Mounjaro.
In a matter of weeks, he lost 25 pounds. What’s more, it fired him up to hit the gym and to start adopting simple longevity habits.
He hasn’t looked back since.
So, not only is Chris a world-class biotech analyst… he’s also a big believer in the power of the next generation of drugs and therapies now being developed.
As John recently told him, “You now LOOK like a person who leads a longevity and biotech letter.” Way to go, Chris.
Next, John turned to an old friend who has been deeply invested in this field for over three decades…
Patrick is no stranger to the Mauldin Economics family. He was formerly a senior editor for Mauldin Economics before accepting a once-in-a-lifetime opportunity to found an anti-aging startup with Chief Wellness Officer of the Cleveland Clinic, Dr. Mike Roizen. (more on him in a moment)
Patrick has been ahead of the curve on cutting-edge technologies for 30+ years. He worked with the Netscape team and founder Marc Andreesen to help develop SSL encryption, which made internet commerce possible. He also wrote a paper on public/private key encryption—the technology underlying Bitcoin—in the late 1990s!
More recently, Patrick has written dozens of papers based on peer-reviewed research of biotechnologies known to or believed to reverse biological age. He is the author of the Methuselah Effect, and he has written over 200 editorials for USA Today. He has also appeared in The Wall Street Journal and on CNN’s Crossfire news program.
Additionally, Patrick has served as a consultant for Fortune 500 companies and has interviewed numerous Nobel Prize-winning scientists and researchers.
Needless to say, we’re thrilled to have Patrick on board. His connections and scientific knowledge are a perfect fit with Chris Wood’s biotech investing expertise.
Every month, Patrick writes about supplements, tips, exercises, and cutting-edge therapies that can dramatically improve your health and lifespan. Some of these therapies can restore the physical vigor of middle-age. All informed by peer reviewed research from experts around the world.
In short, Patrick provides advice to help you slow aging.
He’ll also report on and interpret the latest breakthroughs in age reversal, which are quickly unfolding.
That’s important because the anti-aging science we showed you earlier barely scratches the surface of the stunning progress now being made.
For example, scientists at Johns Hopkins Medicine have helped make a huge breakthrough using small molecule telomerase inducer.
In short, the new drug was given to terminally ill old dogs. It healed their cancers
and osteoporosis and restored them to healthy middle age!
There’s real hope these drugs can eliminate senescence and cell death, and therefore dramatically extend healthy lifespans in humans.
Patrick operates on the inside and follows all the peer-reviewed research… from new therapies coming out of Japan… to little-known longevity supplements… even revolutionary tools like Therapeutic Plasma Exchange, which rejuvenates the genome.
Importantly, Patrick is not a medical doctor, which is a big advantage when it comes to being able to candidly discuss breakthroughs early.
Doctors are often silenced by the medical establishment. They can’t talk about the virtues of a new therapy until it’s been demonstrated beyond doubt, and all the insurance and pharma companies have had their say.
With Patrick as your advisor, you’ll be among the first to get this information—long before your doctor, in all likelihood.
And don’t worry, we have a renowned medical doctor contributing to Transformative Age, too.
They are:
They dig deep into each of these key areas… and expose the breakthrough technologies and companies pushing the boundaries in the field.
The pace of innovation in genetics, neuroscience, and biotechnology is accelerating rapidly… and the implications are profound.
For instance, did you know we’re now making stunning progress in curing diseases that were previously considered uncurable?
Case in point, scientists recently discovered a cause of lupus and a possible way to reverse it…
While a team of scientists from Stanford University and the Salk Institute have found a way to restore brain cells impaired by a rare and life-threatening genetic disorder called Timothy syndrome.
This approach will help researchers develop treatments for other conditions including schizophrenia, epilepsy, ADHD, and autism spectrum disorder.
In fact, one of the doctors involved called it:
From curing rare and deadly diseases… to deafness and blindness… and even aging itself—it’s all on the table now thanks to the advances unfolding.
Just consider the impact of the 2023 Nobel Prize in Medicine.
Thanks to the pioneering research that led to the development of mRNA vaccine technology… we’re already seeing breakthroughs in cancer therapy and personalized medicine.
Then there’s the 2024 Nobel Prize winners. Their discovery of microRNA and its role in gene regulation is a game changer. According to the Nobel Foundation, “The potential of this work to power breakthroughs in medicine is just beginning to be known.”
Yes, we owe it all to the pioneering scientists and doctors at the forefront of these breakthroughs.
But make no mistake… without the work of biotech companies to develop, commercialize, and distribute these life-changing drugs and therapies—millions of people would still be without hope, suffering, and potentially dead.
We’ve seen what can happen when a company transforms innovative science into a revolutionary drug.
Look no further than Novo Nordisk (NVO). Not only did they single-handedly change the future of world-wide obesity, today their revenue is bigger than the entire GDP of their home country, Denmark.
Or take a company like Illumina (ILMN). Though they did not originally map the human genome, they built on that breakthrough by developing next-generation sequencing technology. This dramatically reduced the cost and time needed to sequence genomes.
Today, they are the global leader in DNA sequencing technologies. When they went public in July 2000, their stock price was $16 per share. Thanks to the demand for their research, shares appreciated to an all-time high of $500 during the pandemic.
But it’s not all sunshine and unicorns in the biotech space.
Though exponentially promising, it’s a sector fraught with hazards.
John Mauldin has written at length about this.
Since the 1990s, he’s been passionate about biotech. He’s even served on the boards of two biotech companies.
But he’s the first to admit it’s not easy rowing. Overall, he’s approached investing in biotech like many of his friends have approached investing in gold stocks. If you make 10 small investments, you expect five will go to zero and hope two or three will be home runs. The problem is you never know the winners in advance.
That’s why biotech index funds leave a lot of opportunity on the table.
You need an expert on your side who’s constructed a portfolio in a very specific way.
So, what’s the answer?
In this service, Chris Wood balances our portfolio’s risk versus reward by spreading our holdings (up to 15 stocks) across three buckets:
These are high-risk, pre-revenue, tiny companies.
Every recommendation in this bucket is working on something truly special. A breakthrough that would make the front page of The Wall Street Journal.
For these, we’ll be targeting 3X to 5X gains over an initial three-year holding period. From there, the sky is the limit for a moonshot that can commercialize its breakthrough. Or sell its breakthrough to a deep-pocketed competitor for billions.
Think of these companies as acorns. They won’t all grow into oak trees. But all it takes is one.
With this bucket, the key is to buy before the hype.
Greenwich LifeSciences (GLSI) is a great example of a moonshot play. In 2020, shares jumped 2,941% in a single day, all thanks to positive results from one cancer drug clinical trial.
These are medium-risk, pre-profit, small- and mid-cap companies. They’ve already passed the startup phase and are generating revenue. For these, we’ll be targeting 2X to 3X gains over one- to three-year holding periods.
With this bucket, the key is a catalyst such as FDA approval or getting acquired by a larger company.
Krystal Biotech (KRYS) is a good example of a breakout play. Its stock has appreciated about 300% since 2002, thanks to strong revenue growth and FDA approval of one of their topical gene therapies.
These are profitable mid- and large-cap companies. For this bucket, we’re targeting 100% gains over one- to three-year holding periods.
For these picks, the keys are earnings, cash flow growth, and FDA approval of a big potential drug.
Eli Lilly (LLY) is a great example of a blue-chip biotech play. Thanks to sales of hit therapies Mounjaro and Zepbound, their stock has gained over 320% in the past three years.
In short, the stage is set for a wave of historic activity in this space. Five years from now, you’ll probably wish you had taken advantage of this opportunity.
This is our unique way to invest in the coming revolution.
But it’s not just Chris and Patrick you’ll be hearing from. As a Transformative Age member, you’ll also have exclusive access to something we call…
Every quarter, we hold a special meeting featuring Chris, Patrick, and two very special advisors.
Dr. Roizen is an American anesthesiologist and internist, an award-winning author, and the chief wellness officer at the Cleveland Clinic. He is best-known for developing the RealAge concept and has written 4 NYT #1 bestsellers.
As a pioneering physician in lifestyle medicine, Dr. Roizen has been researching the field of aging and longevity for over 35 years.
Thanks to new medical developments, Dr. Roizen believes we have an 80% probability of making 90-year-olds 40 again… within the next 10 years.
In fact, based on promising recent results, he believes it will be possible to make your heart, brain, back—and every other part of your body that ages—as good as new.
What’s more, beyond drugs, Dr. Roizen believes “your lifestyle choices change the functioning of your DNA switches as surely (and in a much cheaper and easier way) than CRISPR.”
Now, you’ll be able to tap into his deep and ever-expanding knowledge on our quarterly Council calls.
For decades, John has had a passion for longevity and biotech. He’s served on two biotech company boards and is not ashamed to admit he’s been comically overweighted in biotech in his personal portfolio.
Every quarter, he joins us in a deep, spirited, and insightful discussion on everything and anything happening in the biotech and longevity space.
Additionally, as a Transformative Age member, you’ll be able to submit questions to be answered on the quarterly call.
Monthly updates from Patrick Cox.
Every month you’ll get a new, thoroughly researched way to dramatically increase your own healthspan, backed by peer-reviewed research from around the world.
You’ll be among the first in the world to hear about new breakthroughs or therapies as they become available. No one is as plugged into this space as Patrick.
Quarterly council meetings. These are private video calls where you can join John Mauldin, Dr. Mike Roizen, Patrick Cox, and Chris Wood for a lively discussion.
Access to our online community, where you can connect with other Transformative Age members and our team members. We hope to build a strong network of like-minded people who may have access to insights and access to life-enhancing therapies others may not.
The health and wellness Rolodex. A growing database of vetted details on where to go for specific medical issues. There is so much happening in this space right now, but it’s disjointed and disconnected. With this ongoing repository, you’ll always have the best information at your fingertips.
Monthly investment recommendations and updates from Chris Wood. He’ll build a portfolio of up to 15 high-conviction biotech and longevity recommendations, split into 3 groups:
Moonshots—tiny, pre-revenue companies working on big breakthroughs in longevity or biotech. All is takes it one hit to make a big financial difference.
Breakouts—small, revenue generating companies on the verge of a catalyst like FDA approval or a buyout at a premium.
Blue chips—big, profitable companies that give you a lower-risk way to ride the biotech wave.
Urgent alerts as needed, for breaking news or when it’s time to take profits or exit a position.
Transformative Age is a high-end longevity and biotech service designed for a very specific kind of person. All investors and knowledge-seekers will greatly benefit from membership…
But people above age 50, for whom a “fountain of middle age” sounds great—stand to gain the most.
People who want to add more years to their lives… and more life to their years
Investors who want smart exposure to the moonshots that are sure to happen during the biotech and longevity revolution
People looking to understand what factors and simple enhancements matter most to their healthspan and longevity
Investors who know a big change is underway in the longevity and biotech space and would like to invest with more confidence
Investors looking to identify and invest in high-conviction stocks that fit into the three buckets of biotech profits
We want to offer you a full 90 days to decide
if Transformative Age is right for you.
We want you to be 100% happy with your decision to join us. That’s why we’d like to offer you a full 90-Day, 100% Satisfaction Guarantee.
Read the monthly issues. Study the reports. Vet our research and conclusions. Examine our analysis and recommendations. Then if for any reason you’re not completely satisfied with your membership, just contact our friendly customer service team within the first 90 days. They’ll give you a prompt and courteous refund. No third degree. And no hard feelings.
Of course, we think you’re going to love Transformative Age. It’s the next big progression in our work here at Mauldin Economics. But ultimately, it’s your call.
Learn about the latest longevity and biotech advances now unfolding that are set to transform everything… from our health to our portfolios!
Full-year subscription to the Transformative Age service
Monthly longevity and biotech breakthrough updates
Monthly investment recommendations and updates, including specific buy/sell guidance
Special alerts delivered to your inbox whenever there’s an important development concerning our portfolio
Deeply researched longevity and biotech reports
Mobile/tablet friendly
The Transformative Age portfolio with up to 15 of our highest-conviction investment recommendations divided into Chris Wood’s three biotech buckets
The Health and Wellness Rolodex with a growing list of resources on pioneering medical programs and treatment options
Quarterly Council calls with John Mauldin, Dr. Roizen, Patrick Cox, and Chris Wood
Online community where you can interact with the team and fellow members
24/7 online access to the Transformative Age members-only website and app
Click on the questions below to expand and read the answers.
Yes. Our goal is to get you quickly up to speed on the latest longevity breakthroughs as well as the fundamentals of biotech investing. From there, we’ll walk you through our three biotech buckets investing framework. It’s important to remember this is not a get-rich-quick-style service. It is a 1–3-year horizon approach to investing with an eye towards lasting wealth creation.
100%. It’s all there waiting for you. Every longevity and biotech report we’ve published. Every company write-up. Every update, strategy, and longevity insight. We’re not holding anything back. That way you can go through all the resources at your own pace and keep moving forward in your longevity and biotech investing journey.
Yes. You can buy all of our recommendations in any major brokerage account.
Yes, every quarter John and Dr. Roizen will join Patrick Cox and Chris Wood on the members-only Council calls. You’ll be able to submit questions you have before the call and the team will answer as many as possible.
We want you to be 100% happy and confident about your decision. That’s why we’d like to offer you a 90-Day, 100% Satisfaction Guarantee.
Read the reports. Vet our research and conclusions. Join us for a Council call. Examine our analysis and recommendations. Then if for any reason you’re not completely satisfied with your membership just contact our friendly customer service team within the first 90 days. They’ll give you a prompt and courteous refund.
Of course, we think you’re going to love Transformative Age. But ultimately, it’s your call.
Check the box and complete the order form below to join Transformative Age.
Please note all investing carries the risk of loss and you should only speculate with capital you are prepared to lose. The fact that we have made information available to you is neither a recommendation that you enter into a particular transaction nor a representation that any investment described herein is suitable or appropriate for you. Many of the investments described by Mauldin Economics involve significant risks, and you should not enter into any transactions unless you fully understand all such risks and have independently determined that such transactions are appropriate for you. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or complete discussion of the risks which are mentioned. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments. Subscribing to a Mauldin Economics publication does not make us responsible for your investment results, and you will bear the risks of any investment you decide to make. Sometimes our investment recommendations may be wrong or the timing may be off. Furthermore, the investment returns described and detailed above should not be read as a promise or guarantee of your personal returns using Mauldin Economics.
By submitting this order or request, you agree to our Terms & Conditions of Use.
Questions? Need Help? Want to Order Over the Phone?
Call us now at: (602) 626-3100 or (877) 631-6311 (for international callers)